{"classes":[{"categories":[{"measurements":[{"comment":"Here, 'NA' signifies that upper limit of 95% confidence interval could not be estimated due to less number of participants with event.","groupId":"OG000","lowerLimit":"11.07","upperLimit":"NA","value":"20.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"DOR: duration from date of initial documentation of response (PR/better) to date of first documented progressive disease(PD), death or date of censoring if applicable, for responders (PR/better), as assessed by investigator. VGPR/PR: \\>=90% reduction or normal serum IgM values (for VGPR) and \\>=50% (for PR) reduction of serum IgM, with reduction in lymphadenopathy/splenomegaly if present at baseline. PD(at least 1): \\>=25% IgM increase in serum IgM with \\>=500 milligrams per deciliters(mg/dL) increase from nadir(lowest serum IgM value at any time from baseline), confirmation needed if IgM was sole PD criterion; new lymph nodes \\>1.5 centimeters(cm), \\>=50% increase in nadir in sum of product of diameters; 50% increase in longest diameter of previously identified node \\>1cm in short axis; new splenomegaly; new extranodal disease; new/recurrent bone marrow involvement; new symptomatic disease(pleural effusion/Bing Neel syndrome/amyloidosis/light chain deposition/paraprotein mediated disorder).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"OG000","title":"Ibrutinib 420 mg"}],"paramType":"MEDIAN","populationDescription":"Analysis population included responders in all treated analysis set who achieved PR or better.","reportingStatus":"POSTED","timeFrame":"From the date of first documented response up to date of first documented PD or death (Day 1 up to 49.3 months)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}